



November 9, 2007

Dear Friends of ONI,

On October 31, 2007, I announced that Oragenics' SMaRT Replacement Therapy™ had been taken off clinical hold by the FDA and that we were now able to proceed with our second human safety trial with this product designed as an aid in the prevention of tooth decay. There will be additional updates in the coming months regarding our progress in conducting this clinical trial.

Our SMaRT™ technology continues to generate considerable interest from health news services, and I would like to make you aware of two recent interviews that have been conducted with Dr. Jeffrey Hillman, our Chief Scientific Officer, and aired on regional television stations. These interviews were conducted prior to Oragenics receiving the news from the FDA. Please follow the links below (*click or copy/paste*) to view the featured segments on Oragenics' SMaRT Replacement Therapy™.

A cure for cavities? By Dr. Joette Giovinco of FOX 13 Tampa Bay:

<http://www.myfoxtampabay.com/myfox/pages/Home/Detail?contentId=4810982&version=2&locale=EN-US&layoutCode=VSTY&pageId=1.1.1>

Conquering Cavities by Lynn Martinez of FOX 7 Miami:

<http://www3.wsvn.com/features/articles/medicalreports/MI67481>

Both segments have been made available to their FOX affiliates nationwide. Links have also been set up on our web site under Press Room, News, Items of Interest: at

www.oragenics.com/announce_recent.php

Popular Science will also be interviewing Dr. Hillman regarding the SMaRT Replacement Therapy™ technology for an article to be released tentatively in early February 2008.

Finally, there has been considerable press lately regarding the growing threat of deadly staph germs (MRSA or methicillin-resistant *Staphylococcus aureus*). I've included here a link to a recent Bloomberg news release on this topic:

<http://www.bloomberg.com/apps/news?pid=20601109&sid=aGahSHIDYZJM&refer=home>.

This article not only highlights the need for new antibiotics, but provides some measure of the market potential for a successful antibiotic against MRSA. There were thirty new antibiotics approved by the FDA between 1983 and 1992, or an average of three a year. Those numbers have been steadily dwindling in the past fifteen years, with only five new antibiotics (an average of one a year) winning approval between 2003 and today. We recently disclosed in a press release

issued September 5, 2007 that our lead antibiotic candidate, MU1140™, was effective in killing all multi-drug resistant strains of *Staph aureus* tested. This laboratory study included thirty-three clinical isolates of MRSA. We continue to work hard on this most important technology as we move MU1140™ through the required preclinical laboratory and animal testing for safety and effectiveness.

As always, if you have any questions regarding our SMaRT Replacement Therapy™ technology, our novel MU1140 antibiotic, or any other company matters, please contact me and I will be happy to answer your questions.

Best Regards,
Robert T. Zahradnik, PhD
President & CEO